Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled study
Identifieur interne : 000236 ( France/Analysis ); précédent : 000235; suivant : 000237Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled study
Auteurs : Rascol [France] ; David J. Brooks [Royaume-Uni] ; Ehrout R. Brunt [Pays-Bas] ; Amos D. Korczyn [Israël] ; Warner H. Poewe [Autriche] ; Fabrizzio Stocchi [Italie]Source :
- Movement Disorders [ 0885-3185 ] ; 1998-01.
English descriptors
- KwdEn :
Abstract
The efficacies of ropinirole and levodopa were compared after 6 months of treatment in a planned interim analysis of a 5‐year, double‐blind, randomized, multicenter study of patients with early Parkinson's disease requiring dopaminergic therapy. The percentage of improvement in the Unified Parkinson's Disease Rating Scale total motor examination score was significantly higher for levodopa (44%) than for ropinirole (32%). The proportion of “responders” (Unified Parkinson's Disease Rating Scale improvement of at least 30%) did not differ between groups (levodopa, 58%; ropinirole, 48%). There was no difference between the groups for improvement on the Clinical Global Impression scale in patients with Hoehn and Yahr stages I, I.5, or II, but a significantly higher proportion of patients with Hoehn and Yahr stages II.5 or III showed Clinical Global Impression score improvement with levodopa. Emergent adverse events occurred in 84% of patients in both treatment groups, the principal symptom in each group being nausea. The incidence of serious adverse events was low (8% for ropinirole, 9% for levodopa). The results suggest that ropinirole and levodopa are equally effective in less severe Parkinson's disease; in more advanced Parkinson's disease, levodopa is superior.
Url:
DOI: 10.1002/mds.870130111
Affiliations:
- Autriche, France, Israël, Italie, Pays-Bas, Royaume-Uni
- Angleterre, Grand Londres, Groningue (province), Latium
- Groningue, Londres, Rome, Toulouse
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: 001B39
- to stream Main, to step Curation: 001876
- to stream Main, to step Exploration: 001E63
- to stream France, to step Extraction: 000236
Links to Exploration step
ISTEX:C6806C0DBB884E27133D62371C910C21C34E0B4ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled study</title><author><name sortKey="Rascol" sort="Rascol" uniqKey="Rascol" last="Rascol">Rascol</name></author><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name></author><author><name sortKey="Brunt, Ehrout R" sort="Brunt, Ehrout R" uniqKey="Brunt E" first="Ehrout R." last="Brunt">Ehrout R. Brunt</name></author><author><name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D." last="Korczyn">Amos D. Korczyn</name></author><author><name sortKey="Poewe, Warner H" sort="Poewe, Warner H" uniqKey="Poewe W" first="Warner H." last="Poewe">Warner H. Poewe</name></author><author><name sortKey="Stocchi, Fabrizzio" sort="Stocchi, Fabrizzio" uniqKey="Stocchi F" first="Fabrizzio" last="Stocchi">Fabrizzio Stocchi</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C6806C0DBB884E27133D62371C910C21C34E0B4A</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1002/mds.870130111</idno><idno type="url">https://api.istex.fr/document/C6806C0DBB884E27133D62371C910C21C34E0B4A/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001B39</idno><idno type="wicri:Area/Main/Curation">001876</idno><idno type="wicri:Area/Main/Exploration">001E63</idno><idno type="wicri:Area/France/Extraction">000236</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled study</title><author><name sortKey="Rascol" sort="Rascol" uniqKey="Rascol" last="Rascol">Rascol</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology and Clinical Investigation Centre, Faculty of Medicine, INSERM U455, University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurology Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Brunt, Ehrout R" sort="Brunt, Ehrout R" uniqKey="Brunt E" first="Ehrout R." last="Brunt">Ehrout R. Brunt</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, University Hospital, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D." last="Korczyn">Amos D. Korczyn</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of neurology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv</wicri:regionArea><wicri:noRegion>Tel Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Poewe, Warner H" sort="Poewe, Warner H" uniqKey="Poewe W" first="Warner H." last="Poewe">Warner H. Poewe</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University of Innsbruck, Innsbruck</wicri:regionArea><wicri:noRegion>Innsbruck</wicri:noRegion></affiliation></author><author><name sortKey="Stocchi, Fabrizzio" sort="Stocchi, Fabrizzio" uniqKey="Stocchi F" first="Fabrizzio" last="Stocchi">Fabrizzio Stocchi</name><affiliation wicri:level="3"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological Science, University la Sapienza, Rome</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-01">1998-01</date><biblScope unit="volume">13</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="39">39</biblScope><biblScope unit="page" to="45">45</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">C6806C0DBB884E27133D62371C910C21C34E0B4A</idno><idno type="DOI">10.1002/mds.870130111</idno><idno type="ArticleID">MDS870130111</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine agonist</term><term>Double‐blind, controlled study</term><term>Early Parkinson's disease</term><term>Levodopa</term><term>Ropinirole</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The efficacies of ropinirole and levodopa were compared after 6 months of treatment in a planned interim analysis of a 5‐year, double‐blind, randomized, multicenter study of patients with early Parkinson's disease requiring dopaminergic therapy. The percentage of improvement in the Unified Parkinson's Disease Rating Scale total motor examination score was significantly higher for levodopa (44%) than for ropinirole (32%). The proportion of “responders” (Unified Parkinson's Disease Rating Scale improvement of at least 30%) did not differ between groups (levodopa, 58%; ropinirole, 48%). There was no difference between the groups for improvement on the Clinical Global Impression scale in patients with Hoehn and Yahr stages I, I.5, or II, but a significantly higher proportion of patients with Hoehn and Yahr stages II.5 or III showed Clinical Global Impression score improvement with levodopa. Emergent adverse events occurred in 84% of patients in both treatment groups, the principal symptom in each group being nausea. The incidence of serious adverse events was low (8% for ropinirole, 9% for levodopa). The results suggest that ropinirole and levodopa are equally effective in less severe Parkinson's disease; in more advanced Parkinson's disease, levodopa is superior.</div></front></TEI><affiliations><list><country><li>Autriche</li><li>France</li><li>Israël</li><li>Italie</li><li>Pays-Bas</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li><li>Groningue (province)</li><li>Latium</li></region><settlement><li>Groningue</li><li>Londres</li><li>Rome</li><li>Toulouse</li></settlement></list><tree><country name="France"><noRegion><name sortKey="Rascol" sort="Rascol" uniqKey="Rascol" last="Rascol">Rascol</name></noRegion></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name></region></country><country name="Pays-Bas"><region name="Groningue (province)"><name sortKey="Brunt, Ehrout R" sort="Brunt, Ehrout R" uniqKey="Brunt E" first="Ehrout R." last="Brunt">Ehrout R. Brunt</name></region></country><country name="Israël"><noRegion><name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D." last="Korczyn">Amos D. Korczyn</name></noRegion></country><country name="Autriche"><noRegion><name sortKey="Poewe, Warner H" sort="Poewe, Warner H" uniqKey="Poewe W" first="Warner H." last="Poewe">Warner H. Poewe</name></noRegion></country><country name="Italie"><region name="Latium"><name sortKey="Stocchi, Fabrizzio" sort="Stocchi, Fabrizzio" uniqKey="Stocchi F" first="Fabrizzio" last="Stocchi">Fabrizzio Stocchi</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000236 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000236 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:C6806C0DBB884E27133D62371C910C21C34E0B4A
|texte= Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled study
}}
| This area was generated with Dilib version V0.6.23. |  |